Seeking Alpha

BTM

BTM
Send Message
View as an RSS Feed
View BTM's Comments BY TICKER:
Latest  |  Highest rated
  • Vringo's COO stepping down; legal update provided [View news story]
    Given the way management runs the company for their benefit, it should not be a publicly traded company.
    Dec 21, 2014. 03:30 PM | Likes Like |Link to Comment
  • Update: Vringo Post En Banc [View article]
    ..... and the SCOTUS only takes a small fraction of cases that are appealed to it.

    Good luck.
    Dec 17, 2014. 07:38 PM | 1 Like Like |Link to Comment
  • Update: Vringo Post En Banc [View article]
    They may do a reverse stock split. Frankly, who cares? They can try to raise capital but how? I doubt they could find enough fools to buy any shares in a secondary offering to proceed with further litigation.
    Dec 16, 2014. 03:56 PM | 1 Like Like |Link to Comment
  • Update: Vringo Post En Banc [View article]
    This company is uninvestable. Any income is going straight to management.
    Dec 16, 2014. 10:09 AM | 1 Like Like |Link to Comment
  • Vringo -13.4%; en banc petition for Google suit denied [View news story]
    Shareholders are doomed in this stock. Both the courts and management are not a friend of shareholders.
    Dec 15, 2014. 01:32 PM | Likes Like |Link to Comment
  • Ford divulges fuel-economy numbers on 2015 F-150 [View news story]
    Yeah I'm with you. I bet that by next spring, this move by Ford will look awful smart.
    Nov 21, 2014. 03:55 PM | 5 Likes Like |Link to Comment
  • I Don't Care About A Net Asset Value Decline... Prospect Capital Is A Strong Buy [View article]
    I would be ecstatic if Carl Icahn would buy in but I'm not holding my breadth. Frankly any will do. I just don't see management aligned with shareholders at the moment.
    Nov 13, 2014. 08:09 PM | Likes Like |Link to Comment
  • I Don't Care About A Net Asset Value Decline... Prospect Capital Is A Strong Buy [View article]
    PSEC needs an activist shareholder.
    Nov 13, 2014. 09:00 AM | 7 Likes Like |Link to Comment
  • Realty Income: Don't Reach For This Yield Play [View article]
    I agree. I don't think O is a buy at these levels. At 5.5 -6% divy yield, I've been a buyer.
    Nov 12, 2014. 08:15 AM | 1 Like Like |Link to Comment
  • At Current Levels, Geron Has A Very Favorable Risk/Reward Profile [View article]
    User:

    Those are all fair points. Thanks for the reasonable discussion.
    Nov 10, 2014. 09:29 PM | 2 Likes Like |Link to Comment
  • At Current Levels, Geron Has A Very Favorable Risk/Reward Profile [View article]
    I was unaware that this was addressed at an investor update one year ago. It still puzzles me why Wiz cannot acknowledge this. Perhaps he's just delusional. I did not intend to spend so much time debating what is really not debatable but Wiz has 'dug in his heels' over this issue.

    In my original post I made other points that are debatable by reasonable folks. That Imet did have an IC bleed related to treatment is NOT debatable. As I said before, this is the conclusion drawn by Tefferi himself not me. Yet Wiz accuses me of spreading misinformation and "bias". I guess those who are following this thread can decide for themselves who is spreading misinformation and "bias".
    Nov 10, 2014. 08:49 PM | 2 Likes Like |Link to Comment
  • At Current Levels, Geron Has A Very Favorable Risk/Reward Profile [View article]
    Phil:

    I don't need to be lectured on the severity of MF. If they learned from the death on dosing and monitoring to help avoid this AE that's good. However, given the incidence of thrombocytopenia (21%) such an AE should not be unexpected. I take it you know what thrombocytopenia is and what the potential sequelae are.

    I hope that as patients are treated with Imet that the AEs decrease. Thats good for everyone. But the myelo-suppression associated with Imet is significant. Even though many seemed focused on the liver toxicity (which seems mild to me) I find the myelo-suppresion far more significant.
    Nov 10, 2014. 08:26 PM | 2 Likes Like |Link to Comment
  • At Current Levels, Geron Has A Very Favorable Risk/Reward Profile [View article]
    Wiz:

    What don't you understand? It is Tefferi's study that clearly states that there was one death in the study due to IC bleed and it was "related". This isn't my opinioin or interpretation. It is cearly stated that way in the abstract. I don't need to reread anything. Why you try to reject this puzzles me. I ask again, what do you know about the patients' outcomes in Tefferi's study that he doesn't know? What qualifications do you have to determine that the patient death from an IC bleed *wasn't* related to the Imet?
    Nov 10, 2014. 09:45 AM | 2 Likes Like |Link to Comment
  • At Current Levels, Geron Has A Very Favorable Risk/Reward Profile [View article]
    Wiz:

    I you disagree that the one death secondary to IC bleed was "related" to Imet you should take it up with Tefferi. It is his study and his data. I find it odd that you think you know more about his study than he does and telling that you are quick to reject any data which is negative regarding Imet.
    Nov 9, 2014. 08:44 PM | 2 Likes Like |Link to Comment
  • At Current Levels, Geron Has A Very Favorable Risk/Reward Profile [View article]
    Gob:

    That Imet is better than Jackafi in treating MF only confirms exactly that.
    It does not follow that Imet is a universal cure for cancer. Once again you are quick to make conclusions where none can reasonably be made.

    I also would point out that Geron halted a study of Imet in non small cell lung cancer, once again due to lack of results.

    That Imet is effective in 20% of MF patients supports my contention that specific drugs will be necessary to treat specific cancers as opposed to a 'silver bullet' cure for all cancers as you hope. Imetelsat isn't even a universal cure for MF, just a specific type that is not well understood at this time.
    Nov 8, 2014. 09:36 PM | 1 Like Like |Link to Comment
COMMENTS STATS
373 Comments
625 Likes